--- title: "U.S. stock market quick update: 20/20 Biolabs launched a new product but failed to boost its stock price, instead suffering a 28.20% plunge. Where is the market confidence?" description: "20/20 Biolabs fell 28.20%; Alcon rose 2.20%, with a transaction volume of USD 855.5 million; Medline rose 1.37%, with a transaction volume of USD 520.9 million; Acelity rose 0.82%, with a transaction " type: "news" locale: "en" url: "https://longbridge.com/en/news/276906336.md" published_at: "2026-02-25T15:02:44.000Z" --- # U.S. stock market quick update: 20/20 Biolabs launched a new product but failed to boost its stock price, instead suffering a 28.20% plunge. Where is the market confidence? > 20/20 Biolabs fell 28.20%; Alcon rose 2.20%, with a transaction volume of USD 855.5 million; Medline rose 1.37%, with a transaction volume of USD 520.9 million; Acelity rose 0.82%, with a transaction volume of USD 342.3 million; Cooper Surgical fell 0.90%, with a market value of USD 16.2 billion **U.S. Stock Market Midday Update** 20/20 Biolabs fell 28.20%. Based on recent key news: 1. On February 25, 20/20 Biolabs launched a longevity blood test and chronic disease risk assessment and management solution based on IBM AI capabilities. This move aimed to expand the company's product line and enhance market competitiveness, but failed to immediately boost the stock price, instead raising investor concerns about the market acceptance of the new product, leading to a significant drop in stock price. 2. On February 25, the company stated in a forward-looking statement that while it is optimistic about future results, it cannot guarantee achieving the expected outcomes. This statement exacerbated market uncertainty regarding the company's future performance, further depressing the stock price. There are doubts about the market acceptance of the new product, increasing risks. **Stocks with High Trading Volume in the Industry** Alcon rose 2.20%. Based on recent news: 1. On February 24, Alcon released a strong Q4 2025 earnings report, with sales growth of 9%, reaching $2.7 billion, driving the stock price up. Source: Reuters 2. On February 24, Alcon projected a net sales growth of 5% to 7% for 2026, with core diluted earnings per share growth of 9% to 12%, instilling confidence in the company's future performance. Source: Reuters 3. On February 24, Alcon announced the launch of a new product, PanOptix Pro, which performed well in the U.S. market, further boosting investor confidence. Source: Reuters The medical device industry is performing strongly overall, with high demand for innovative products. Medline rose 1.37%, with a trading volume of $52.09 million. Based on recent key news: 1. On February 25, Medline reported its full-year 2025 results, with net sales growth of 11.5%, but net income fell by 3.6%. Despite the decline in net income, increased customer confidence drove the stock price up. Source: Benzinga 2. On February 25, Medline CEO Jim Boyle stated that the IPO will drive the company’s continued investment for growth, expecting organic sales growth of 8% to 9% in 2026. This optimistic outlook boosted market sentiment. Source: SEC filings 3. On February 25, Medline signed a major supplier agreement with McLaren Health Care, expanding its product portfolio and distribution network, enhancing market competitiveness. Source: Public Technologies The healthcare industry is experiencing strong growth, with a focus on cost pressures. Aiqi Technology rose 0.82%. Based on recent key news: 1. On February 23, Aiqi Technology's financial report showed a revenue growth of 5.3%, exceeding analyst expectations by 1.2%. This positive financial result drove the stock price up by 8.9%. Source: Zhitong Finance 2. On February 23, the overall performance of the medical equipment and supplies industry was poor, with an average stock price decline of 3.4% over the past month. However, Aiqi Technology performed exceptionally well during this period, with a stock price increase of 0.82%. Source: Wall Street Insight 3. On February 23, concerns about potential tariff and corporate tax changes led to industry volatility, but Aiqi Technology's robust performance alleviated some investor worries. Source: Jinshi Data The medical equipment industry has recently performed poorly, with increased volatility. **Stocks ranked at the top of the industry by market capitalization** Cooper Medical fell 0.90%. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. no\_news ### Related Stocks - [AIDX.US - 20/20 Biolabs](https://longbridge.com/en/quote/AIDX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Roth MKM 繼續維持對 HEALWELL AI (AIDX) 的買入評級 | Roth MKM 分析師 Kyle Bauser 對 HEALWELL AI (AIDX) 維持了買入評級，目標價為 2.50 加元。Bauser 的平均回報為 -13.0%，成功率為 35.92%，專注於醫療保健行業。此外，Haywood | [Link](https://longbridge.com/en/news/277098766.md) | | C3.ai 在財報發佈後股價暴跌 20%。現在是否應該趁低買入這隻 AI 股票？ | C3.ai 在財報發佈後暴跌 20%。你現在應該買入這隻人工智能股票嗎？ | [Link](https://longbridge.com/en/news/277084149.md) | | NuScale Power 的股票是否會漲到 20 美元？ | NuScale Power 的股價從其 52 周高點下跌了 77%。但每股 20 美元的價格可能在不久的將來出現 | [Link](https://longbridge.com/en/news/277324152.md) | | 根據國際原子能機構的定義，125 公斤的鈾如果被濃縮到 20%，理論上足以在進一步濃縮後製造一枚核彈 | 根據國際原子能機構（IAEA）的定義，125 公斤濃縮至 20% 的鈾在理論上足夠，如果進一步濃縮，可以製造一枚核彈 | [Link](https://longbridge.com/en/news/277211705.md) | | 20 年前投資於康耐視科技的 100 美元今天將價值多少 | Cognex（納斯達克代碼：CGNX）在過去 20 年中實現了平均年回報率 10.8%，超出市場 2.1%。目前市值為 93.8 億美元，20 年前投資 100 美元購買 CGNX 股票，現在的價值為 784.58 美元，基於當前價格 56 | [Link](https://longbridge.com/en/news/276752386.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.